Meeting NewsVideo

VIDEO: Intra-articular sprifermin prevented cartilage loss in patients with knee OA

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Marc C. Hochberg, MD, spoke about a study that evaluated the efficacy and safety of intra-articular sprifermin in patients with symptomatic radiographic knee osteoarthritis. When sprifermin was administered at a higher dose at 6 months or 12 months it slowed progression of joint space loss or cartilage thinning and was associated with an increase in cartilage thickness.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Marc C. Hochberg, MD, spoke about a study that evaluated the efficacy and safety of intra-articular sprifermin in patients with symptomatic radiographic knee osteoarthritis. When sprifermin was administered at a higher dose at 6 months or 12 months it slowed progression of joint space loss or cartilage thinning and was associated with an increase in cartilage thickness.

    See more from American College of Rheumatology Annual Meeting